Autolus Therapeutics Stock News

Autolus Therapeutics plc (NASDAQ:AUTL) was the target of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 2,060,000 shares, a drop of 17.6% from the November 15th total of 2,500,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the days-to-cover ratio []

Brokerages forecast that Autolus Therapeutics plc (NASDAQ:AUTL) will report sales of $270,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Autolus Therapeutics earnings. The lowest sales estimate is $240,000.00 and the highest is $300,000.00. Autolus Therapeutics posted sales of $400,000.00 during the same quarter last year, which would []

Brokerages predict that Autolus Therapeutics plc (NASDAQ:AUTL) will announce earnings per share (EPS) of ($0.40) for the current quarter, according to Zacks. Three analysts have issued estimates for Autolus Therapeutics earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.15). Autolus Therapeutics posted earnings per share of []

Autolus Therapeutics plc (NASDAQ:AUTL) was the target of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 2,500,000 shares, an increase of 39.7% from the October 31st total of 1,790,000 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is [] The post Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update appeared first on ETF Daily News .

Marshall Wace LLP raised its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 200.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 297,749 shares of the companys stock after buying an additional 198,736 shares during the period. Marshall Wace LLPs holdings in Autolus []

Goldman Sachs Group Inc. boosted its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 5,559.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 650,496 shares of the companys stock after buying an additional 639,002 shares during the quarter. Goldman []

Roblox Corp (NYSE: RBLX) shares jumped 30% after hours on Monday after the company posted robust fiscal Q3 results thanks to demand surge with the easing of COVID-19 restrictions. As a result, the vid

A private equity firm is taking a $100 million stake in the biotech.

Chinese education stocks are moving higher on Monday as reports claim China will allow companies to resume their after-school tutoring. The post Chinese Stocks Alert: The Turnaround Story Driving TAL,

Autolus Therapeutics (AUTL) stock is surging higher in trading Monday following news of a major investment in the company. The post AUTL Stock: Why Little-Known Autolus Therapeutics Is Rocketing Highe

Shares of Autolus Therapeutics plc (NASDAQ: AUTL) jumped about 30% in premarket trading on Monday after it said Blackstone Life Sciences agreed to invest up to $250 million to fund the development of

The stock price of Autolus Therapeutics PLC (NASDAQ: AUTL) increased by over 25% pre-market today. This is why it happened.

- Demonstrates progress on the Company's commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA

Autolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q3 2021 Results - Earnings Call Transcript

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t